Market Research Report

A quick peek into the report

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis

Focus on Product, Technology, and End User - Analysis and Forecast, 2021-2030

 
Some Faq's

Frequently Asked Questions

The global nucleic acid therapeutics CDMO market is expected to reach $4,463.7 Million by 2030, with a CAGR of 11.09 % during the forecast period 2021-2030.
The top market players are Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG, Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc., QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation.
Factors driving the growth of the global nucleic acid therapeutics CDMO market are accelerating shift of the pharmaceutical market toward innovative biologic and cell and gene therapy products, reduction in overall manufacturing cost at CDMOs, and rising approvals of nucleic acid therapeutics.
The main challenges restricting the growth of the global nucleic acid therapeutics CDMO market are lack of expertise in nucleic acid manufacturing, supply chain and logistical challenges, and difficult therapeutic classification due to wide variety of nucleic acids.
The potential opportunities that are likely to boost the growth of the global nucleic acid therapeutics CDMO market are increasing outsourcing trend among pharmaceutical companies, accelerating research and development along with technology, and growth in developing countries.
Similar Product

You may also like

Global Nucleic Acid Isolation and Purification Market
Published Year: 2021

Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Da

The nucleic acid isolation and purification market is projected to reach $5,010.3 million by...